Persistency of response to omalizumab therapy in severe allergic (IgE‐mediated) asthma
暂无分享,去创建一个
J. Bousquet | M. Humbert | Z. Siergiejko | C. Peckitt | R. Maykut | G. Peachey | E. Świebocka | K. Rabe | N. Smith | K. Rabe | J. Leo | C. Peckitt | J. Bousquet | Jo Leo
[1] D. MacGlashan,et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. , 2009, The Journal of allergy and clinical immunology.
[2] U. Wahn,et al. Relationship between pretreatment specific IgE and the response to omalizumab therapy , 2009, Allergy.
[3] L. Cardell,et al. The size of the disease relevant IgE antibody fraction in relation to ‘total‐IgE’ predicts the efficacy of anti‐IgE (Xolair®) treatment , 2009, Allergy.
[4] S. Holgate,et al. Safety and tolerability of omalizumab , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[5] K. Chung,et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. , 2008, Respiratory medicine.
[6] How to evaluate a patient's response to anti-IgE , 2007, European Respiratory Review.
[7] J. Bousquet,et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. , 2007, Respiratory medicine.
[8] J. Bousquet,et al. The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma , 2005, Allergy.
[9] J Bousquet,et al. Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.
[10] A. Togias,et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. , 1997, Journal of immunology.
[11] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .